FY2028 Earnings Forecast for AVDL Issued By Leerink Partnrs

Avadel Pharmaceuticals PLC. (NASDAQ:AVDL) – Equities research analysts at Leerink Partnrs cut their FY2028 earnings estimates for shares of Avadel Pharmaceuticals in a research report issued to clients and investors on Thursday, October 23rd. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings per share of $1.78 for the year, down from their prior forecast of $1.80. Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Avadel Pharmaceuticals’ current full-year earnings is ($0.51) per share. Leerink Partnrs also issued estimates for Avadel Pharmaceuticals’ FY2029 earnings at $2.68 EPS.

AVDL has been the subject of a number of other reports. Leerink Partners reaffirmed a “market perform” rating and set a $18.50 price objective on shares of Avadel Pharmaceuticals in a report on Thursday, October 23rd. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Avadel Pharmaceuticals in a report on Friday, August 8th. Piper Sandler lowered shares of Avadel Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 22nd. Zacks Research lowered shares of Avadel Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 7th. Finally, Craig Hallum lowered shares of Avadel Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 22nd. Three equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $18.72.

Avadel Pharmaceuticals Price Performance

Shares of AVDL opened at $18.56 on Monday. Avadel Pharmaceuticals has a 1 year low of $6.38 and a 1 year high of $18.65. The company has a 50 day simple moving average of $15.41 and a two-hundred day simple moving average of $11.72. The firm has a market cap of $1.80 billion, a P/E ratio of -618.67 and a beta of 1.46.

Avadel Pharmaceuticals (NASDAQ:AVDL) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.08. Avadel Pharmaceuticals had a negative net margin of 1.32% and a negative return on equity of 3.73%. The business had revenue of $68.13 million during the quarter, compared to analyst estimates of $60.28 million. During the same period last year, the firm posted ($0.14) EPS. The company’s revenue was up 64.1% on a year-over-year basis. Avadel Pharmaceuticals has set its FY 2025 guidance at EPS.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of AVDL. Two Seas Capital LP boosted its stake in Avadel Pharmaceuticals by 24.4% during the second quarter. Two Seas Capital LP now owns 6,155,074 shares of the company’s stock worth $54,472,000 after buying an additional 1,208,625 shares during the period. Geode Capital Management LLC boosted its stake in Avadel Pharmaceuticals by 82.3% during the second quarter. Geode Capital Management LLC now owns 2,169,018 shares of the company’s stock worth $19,198,000 after buying an additional 979,422 shares during the period. Brandes Investment Partners LP boosted its stake in Avadel Pharmaceuticals by 14.5% during the second quarter. Brandes Investment Partners LP now owns 6,487,642 shares of the company’s stock worth $57,416,000 after buying an additional 820,467 shares during the period. Invesco Ltd. boosted its stake in Avadel Pharmaceuticals by 1,407.6% during the second quarter. Invesco Ltd. now owns 748,875 shares of the company’s stock worth $6,628,000 after buying an additional 699,201 shares during the period. Finally, Nuveen LLC purchased a new position in Avadel Pharmaceuticals during the first quarter worth $4,055,000. 69.19% of the stock is owned by hedge funds and other institutional investors.

About Avadel Pharmaceuticals

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.